Pain, Quality of Life
Conditions
Keywords
Meperidine, Fentanyl, Pain management, brachytherapy
Brief summary
Purpose: To compare the pain level and quality of life of the two sedation regimens consisting of diazepam in combination with meperidine or fentanyl. Materials and methods: A total of 40 patients (160 sessions of brachytherapy), unselected brachytherapy out patients at Chulabhorn Hospital, Thailand were enrolled with informed consent and randomized to receive meperidine or fentanyl. Data of perceived pain (according to standard 10-cm visual analog scales \[VAS\]), and perceived Quality of life (EQ-5D) were collected. Patients and all brachytherapy staffs directly involved with the procedure were blinded about the drug used.
Detailed description
Methods Patients Unselected, forty female adults, aged 20 years old or older, diagnosed with cervical cancer and treated with brachytherapy as outpatients at Chulabhorn Hospital, Thailand between June 2011 and September 2012 were enrolled in the study with their informed consents. The study was approved by The Chulabhorn Research Institutional Review Board and Chulabhorn Ethics committee. All the patients were treated with four sessions of ICRT(Intracavitary Radiation Therapy). Inclusion criteria were: Age 20 - 80 years, can understand and provide information, no trouble hearing and good conscious, agree to participated and had performance levels at ECOG 0-2. The patients were randomized to receive either meperidine (1 mg/kg) or fentanyl (1 ug/kg) with diazepam 10 mg both. Nursing staffs who prepared the drugs picked the drugs from lotteries organized into 6 lots on it. Procedures Perceived pain score according to standard 10-cm visual analog scales (VAS) was assessed prior to treatment and every 15 minutes from the start to the end of the ICRT procedure. Perceived Quality of life (EQ-5D) was assessed before the treatment and immediately after the completion of each brachytherapy treatment session. Information regarding which drug was used was concealed to all the patients and brachytherapy staffs directly involved with the procedures. The procedures involved a radiation oncologist, two nurses, a practical nurse, a radiotherapist, and a medical physicist. Firstly, before the procedure the patients must NPO(Nothing per oral) for 6 hours and was inserted with intravenous catheter for IV sedation drug depending on the randomized drug that they received. Secondly, the patients laid down on brachytherapy stretcher and were treated according to the standard ICRT protocol. Each randomized patient had 4 fractions of ICRT, so a single patient will receive Fentanyl and Diazepam 2 fractions and Meperidine and Diazepam 2 fractions. The drugs used were diluted with normal saline to 10 ml. and labeled as Protocol drug. The actual content within the syringes was known only to a nurse that did not directly involve in the study. Syringes prepared for the meperidine group contained 50 mg of meperidine, while syringes prepared for the fentanyl group contained 100 mg of fentanyl. Both drugs were drawn into 10-cc syringes and appeared colorless.
Interventions
Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
Sponsors
Study design
Eligibility
Inclusion criteria
* Aged 20 years old or older, * Diagnosed with cervical cancer * On course of external Radiation therapy * Treated with brachytherapy 4 times.
Exclusion criteria
* Pregnant * Previously underwent intracavitary brachytherapy * Illiterate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain Score | From date of the first fraction until date of the last fraction of brachytherapy, once a week for four weeks | Perceived pain score according to standard 10-cm visual analog scales (VAS) was assessed before injection of medicine for every 15 minutes up to 120 minutes.The minimum and maximum scores were 0, 10. Score 0 means no pain, 1-3 mild pain, 4-6 moderate pain, 7-9 severe pain and 10 worst pain. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life | From date of the first fraction of brachytherapy until date of the last fraction of brachytherapy,once a week for 4 weeks | Perceived Quality of life (EQ-5D) was assessed before the first brachytherpy and immediately after completion of each of the 4 brachytherapy fractions. The EQ-5D have 5 dimensions: mobility, self-care, usual activities, topics each content 3 responses: no problems, some problems, extreme problems. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Ovoids Size | after complete applicator insertion. | Size of ovoids that a pair part of brachytherapy applicator insert in vagina trough cervix. |
| Tumor Size | Before insert applicator in each fraction of brachytherapy. | Size of tumor at cervix measured by the doctor before insert applicator. |
| Meperidine Dose | after complete treatment. | Sum of meperidine dose when finish each fraction of brachytherapy |
| Fentanyl Dose | after complete treatment. | Sum of fentanyl dose when finish each fraction of brachytherapy |
Participant flow
Recruitment details
The study design is cross-over in female outpatients with cervical cancer (age, 20-80 years) stage IB-IVB treated with four fractions of brachytherapy from June 2013 to September 2014 were enrolled in the study.
Pre-assignment details
Forty patients with cervical cancer were enrolled in the study. The exclusion criteria were prior pelvic brachytherapy and a history of allergy to meperidine, fentanyl, or benzodiazepine and none were subsequently excluded.
Participants by arm
| Arm | Count |
|---|---|
| All Participants All participants who enrolled to this study. | 40 |
| Total | 40 |
Baseline characteristics
| Characteristic | All Participants |
|---|---|
| Age, Continuous | 56.7 years STANDARD_DEVIATION 12.9 |
| FIGO stage IB | 5 participants |
| FIGO stage IIA1 | 2 participants |
| FIGO stage IIA2 | 1 participants |
| FIGO stage IIB | 16 participants |
| FIGO stage IIIB | 15 participants |
| FIGO stage IVB | 1 participants |
| Radiation modality 2D, two-dimensional | 30 participants |
| Radiation modality 3D conformal | 10 participants |
| Sex: Female, Male Female | 40 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 40 | 0 / 40 |
| other Total, other adverse events | 0 / 40 | 0 / 40 |
| serious Total, serious adverse events | 0 / 40 | 0 / 40 |
Outcome results
Pain Score
Perceived pain score according to standard 10-cm visual analog scales (VAS) was assessed before injection of medicine for every 15 minutes up to 120 minutes.The minimum and maximum scores were 0, 10. Score 0 means no pain, 1-3 mild pain, 4-6 moderate pain, 7-9 severe pain and 10 worst pain.
Time frame: From date of the first fraction until date of the last fraction of brachytherapy, once a week for four weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Meperidine | Pain Score | 15 minute | 0.59 units on a scale | Standard Deviation 1.38 |
| Meperidine | Pain Score | 60 minute | 0.61 units on a scale | Standard Deviation 1.48 |
| Meperidine | Pain Score | 0 minute | 0.49 units on a scale | Standard Deviation 1.18 |
| Meperidine | Pain Score | 75 minute | 0.49 units on a scale | Standard Deviation 0.99 |
| Meperidine | Pain Score | 30 minute | 1.05 units on a scale | Standard Deviation 1.76 |
| Meperidine | Pain Score | 90 minute | 0.24 units on a scale | Standard Deviation 0.8 |
| Meperidine | Pain Score | 105 minute | 0.24 units on a scale | Standard Deviation 0.8 |
| Meperidine | Pain Score | baseline | 0.04 units on a scale | Standard Deviation 0.25 |
| Meperidine | Pain Score | 120 minute | 0.24 units on a scale | Standard Deviation 0.8 |
| Meperidine | Pain Score | 45 minute | 1.33 units on a scale | Standard Deviation 2.09 |
| Fentanyl | Pain Score | 120 minute | 0.13 units on a scale | Standard Deviation 0.58 |
| Fentanyl | Pain Score | baseline | 0.14 units on a scale | Standard Deviation 0.55 |
| Fentanyl | Pain Score | 0 minute | 0.40 units on a scale | Standard Deviation 1.16 |
| Fentanyl | Pain Score | 15 minute | 0.65 units on a scale | Standard Deviation 1.21 |
| Fentanyl | Pain Score | 30 minute | 1.24 units on a scale | Standard Deviation 2.21 |
| Fentanyl | Pain Score | 45 minute | 1.70 units on a scale | Standard Deviation 2.48 |
| Fentanyl | Pain Score | 60 minute | 0.81 units on a scale | Standard Deviation 1.83 |
| Fentanyl | Pain Score | 75 minute | 0.53 units on a scale | Standard Deviation 1.12 |
| Fentanyl | Pain Score | 105 minute | 0.13 units on a scale | Standard Deviation 0.58 |
| Fentanyl | Pain Score | 90 minute | 0.13 units on a scale | Standard Deviation 0.58 |
Quality of Life
Perceived Quality of life (EQ-5D) was assessed before the first brachytherpy and immediately after completion of each of the 4 brachytherapy fractions. The EQ-5D have 5 dimensions: mobility, self-care, usual activities, topics each content 3 responses: no problems, some problems, extreme problems.
Time frame: From date of the first fraction of brachytherapy until date of the last fraction of brachytherapy,once a week for 4 weeks
Population: Pain score in each fraction.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Meperidine | Quality of Life | Some problem in self-care | 11 participants |
| Meperidine | Quality of Life | Severe problem in usual activities | 2 participants |
| Meperidine | Quality of Life | Some problems in mobility | 16 participants |
| Meperidine | Quality of Life | No problem in pain/discomfort | 27 participants |
| Meperidine | Quality of Life | Severe problem in self-care | 0 participants |
| Meperidine | Quality of Life | Some problem in pain/discomfort | 49 participants |
| Meperidine | Quality of Life | No problem in self-care | 68 participants |
| Meperidine | Quality of Life | Severe problem in pain/discomfort | 3 participants |
| Meperidine | Quality of Life | No problem in usual activities | 55 participants |
| Meperidine | Quality of Life | No problem in anxiety/depression | 46 participants |
| Meperidine | Quality of Life | Severe problems in mobility | 1 participants |
| Meperidine | Quality of Life | Some problem in anxiety/depression | 32 participants |
| Meperidine | Quality of Life | Some problem in usual activities | 22 participants |
| Meperidine | Quality of Life | Severe problem in anxiety/depression | 1 participants |
| Meperidine | Quality of Life | No problems in mobility | 62 participants |
| Fentanyl | Quality of Life | Severe problem in anxiety/depression | 2 participants |
| Fentanyl | Quality of Life | No problems in mobility | 58 participants |
| Fentanyl | Quality of Life | Some problems in mobility | 18 participants |
| Fentanyl | Quality of Life | Severe problems in mobility | 1 participants |
| Fentanyl | Quality of Life | No problem in self-care | 69 participants |
| Fentanyl | Quality of Life | Some problem in self-care | 6 participants |
| Fentanyl | Quality of Life | Severe problem in self-care | 2 participants |
| Fentanyl | Quality of Life | No problem in usual activities | 53 participants |
| Fentanyl | Quality of Life | Some problem in usual activities | 21 participants |
| Fentanyl | Quality of Life | Severe problem in usual activities | 3 participants |
| Fentanyl | Quality of Life | No problem in pain/discomfort | 23 participants |
| Fentanyl | Quality of Life | Some problem in pain/discomfort | 53 participants |
| Fentanyl | Quality of Life | Severe problem in pain/discomfort | 1 participants |
| Fentanyl | Quality of Life | No problem in anxiety/depression | 42 participants |
| Fentanyl | Quality of Life | Some problem in anxiety/depression | 33 participants |
Fentanyl Dose
Sum of fentanyl dose when finish each fraction of brachytherapy
Time frame: after complete treatment.
Population: Participants received 4 fraction of brachytherapy. Thus all 160 fractions separated to two group of drug and analysis data in each group.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Meperidine | Fentanyl Dose | 100.18 ug. | Standard Deviation 0.32 |
Meperidine Dose
Sum of meperidine dose when finish each fraction of brachytherapy
Time frame: after complete treatment.
Population: Participants received 4 fraction of brachytherapy. Thus all 160 fractions separated to two group of drug and analysis data in each group.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Meperidine | Meperidine Dose | 50.13 mg. | Standard Deviation 0.26 |
Ovoids Size
Size of ovoids that a pair part of brachytherapy applicator insert in vagina trough cervix.
Time frame: after complete applicator insertion.
Population: Each patient was treated with 4 fractions of brachytherapy.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Meperidine | Ovoids Size | 2 Centimeter |
| Fentanyl | Ovoids Size | 2 Centimeter |
Tumor Size
Size of tumor at cervix measured by the doctor before insert applicator.
Time frame: Before insert applicator in each fraction of brachytherapy.
Population: Participants received 4 fraction of brachytherapy. Thus all 160 fractions separated to two group of drug and analysis data in each group.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Meperidine | Tumor Size | 2.23 CM. | Standard Deviation 1.29 |
| Fentanyl | Tumor Size | 2.21 CM. | Standard Deviation 1.25 |